NVLNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVLNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Novelion Therapeutics's total inventories for the quarter that ended in Mar. 2019 was $13.4 Mil. Novelion Therapeutics's average total inventories from the quarter that ended in Dec. 2018 to the quarter that ended in Mar. 2019 was $13.1 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Novelion Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2019 was $-20.08.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Novelion Therapeutics's Days Inventory for the three months ended in Mar. 2019 was 78.40.
Inventory Turnover measures how fast the company turns over its inventory within a year. Novelion Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2019 was 1.16.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Novelion Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2019 was 0.41.
The historical data trend for Novelion Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | - | - | 15.72 | 15.89 | 12.75 |
Novelion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
Total Inventories | Get a 7-Day Free Trial | 13.38 | 13.25 | 19.12 | 12.75 | 13.41 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Novelion Therapeutics (OTCPK:NVLNF) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Novelion Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2019 is
Net-Net Working Capital Per Share (Q: Mar. 2019 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (51.919 | + | 0.75 * 26.875 | + | 0.5 * 13.407 | - | 461.069 |
- | 0 | - | 0) | / | 19.043 | ||
= | -20.08 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Novelion Therapeutics's Days Inventory for the three months ended in Mar. 2019 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2019 ) | / | Cost of Goods Sold (Q: Mar. 2019 ) | * | Days in Period |
= | 13.076 | / | 15.219 | * | 365 / 4 | |
= | 78.40 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Novelion Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2019 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Mar. 2019 ) | / | Average Total Inventories (Q: Mar. 2019 ) |
= | 15.219 | / | 13.076 | |
= | 1.16 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Novelion Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2019 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Mar. 2019 ) | / | Revenue (Q: Mar. 2019 ) |
= | 13.076 | / | 32.2 | |
= | 0.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Novelion Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Stonepine Capital, L.p. | 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Michael Dennis Price | officer: Chief Financial Officer | |
Benjamin Harshbarger | officer: See Remarks | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
John J Orloff | director | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
Mark Corrigan | director | |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
John C Thomas | director | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
Murray Stewart | officer: Executive Vice President, R&D | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Mary T Szela | director, officer: Chief Executive Officer | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired Marketwired • 07-05-2019
By Marketwired Marketwired • 09-24-2018
By Marketwired Marketwired • 07-03-2018
By Marketwired Marketwired • 08-13-2019
By GlobeNewswire GlobeNewswire • 08-21-2019
By GlobeNewswire GlobeNewswire • 05-21-2019
By PRNewswire PRNewswire • 11-12-2018
By Marketwired Marketwired • 10-04-2019
By Marketwired Marketwired • 05-21-2019
By Marketwired Marketwired • 10-08-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.